Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14363623 | 0.83 | L3MBTL1 (0.50) | L3MBTL1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL18195999 | 0.80 | L3MBTL1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL11921134 | 0.79 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL17071981 | 0.78 | L3MBTL1 (0.45) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL6900814 | 0.78 | NPC1 (0.52) | L3MBTL1NPC1RAB9ALMNACASP3 | |
| SCHEMBL12266888 | 0.77 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL2642324 | 0.77 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL11921136 | 0.77 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL18939806 | 0.77 | ACHE (0.48) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL16067420 | 0.76 | NPC1 (0.50) | L3MBTL1NPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9403813-B2 | Azetidine amide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403813-B2 | Azetidine amide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| WO-2015095442-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014141065-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014057435-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | L3MBTL1 4510/4885NPC1 1202/4885RAB9A 2680/4885 |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | L3MBTL1 4861/4885NPC1 588/4885RAB9A 739/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | L3MBTL1 4811/4885NPC1 1248/4885RAB9A 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.